Cobenfy – przełom w leczeniu schizofrenii
Keywords:
Cobenfy, Schizofrenia, Innowacyjne leczenieSynopsis
Cobenfy, nowy lek zatwierdzony przez Agencję ds. Żywności i Leków (FDA), łączy dwa składniki aktywne: ksanomelinę i chlorek trospium, oferując innowacyjne podejście do leczenia schizofrenii. Schizofrenia jako choroba o wieloczynnikowym patomechanizmie charakteryzuje się złożonymi objawami, które można podzielić na pozytywne, negatywne i poznawcze. Tradycyjne terapie, oparte głównie na lekach przeciwpsychotycznych, często nie są wystarczająco skuteczne, zwłaszcza w przypadku objawów negatywnych i poznawczych, a także wiążą się z licznymi działaniami niepożądanymi, co prowadzi do niskiej adherencji pacjentów. Cobenfy, działając na receptory cholinergiczne, może skutecznej łagodzić objawy schizofrenii, minimalizując jednocześnie ryzyko wystąpienia typowych efektów ubocznych neuroleptyków pierwszej i drugiej generacji, takich jak przyrost masy ciała czy zaburzenia ruchowe. W badaniach klinicznych Cobenfy wykazał znaczną skuteczność w redukcji zarówno objawów pozytywnych, jak i negatywnych, co czyni go obiecującą alternatywą dla tradycyjnych terapii. Dodatkowo, Cobenfy jest również badany pod kątem zastosowania w leczeniu choroby Alzheimera oraz zaburzeń afektywnych dwubiegunowych, co może otworzyć nowe możliwości terapeutyczne. Wraz z rozwojem naszej wiedzy na temat schizofrenii i jej leczenia, Cobenfy może stanowić krok w kierunku bardziej zindywidualizowanego i skutecznego podejścia do terapii, co jest niezwykle istotne w kontekście rosnącej liczby pacjentów z tym zaburzeniem na całym świecie.
References
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. Molecules, 23(8), 2087. doi:10.3390/molecules23082087
Thorat, N. M. (n.d.). Schizophrenia: A Comprehensive Systematic Review of Current Knowledge, Treatment Approaches, and Disparities ISSN: 2455-2631
Babu Deva Irakkam, Mercy & Joseph, Jerly Helan Mary & Kandasamy, Mahesh. (2023). Aberrant Hippocampal Neuroregenerative Plasticity in Schizophrenia: Reactive Neuroblostosis as a Possible Pathocellular Mechanism of Hallucination. doi:10.20944/preprints202312.0820.v1
Volkan, K. (2020). Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment. Journal of Health and Medical Sciences, 3(4). doi: 10.31014/aior.1994.03.04.143
Noor, R., & Qazi, M. S. (2025). Cobenfy: A new ray of hope in schizophrenia treatment. Asian Journal of Psychiatry, 103, 104318. doi: 10.1016/j.ajp.2024.104318
Kidambi, N., Elsayed, O. H., El-Mallakh, R. S., Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, 40202, USA Mood Disorders Research Program Depression Center Department of Psychiatry and Behavioral Sciences School of Medicine University of Louisville 40202 Louisville KY USA, & Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, 40202, USA Mood Disorders Research Program Depression Center Department of Psychiatry and Behavioral Sciences University of Louisville School of Medicine 40202 Louisville KY USA. (n.d.). Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia.
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. The Lancet, 388(10039), 86–97. doi: 10.1016/s0140-6736(15)01121-6
Aricioglu, Feyza & Sahin Ozkartal, Ceren & Unal, Gokhan & Dursun, Semra & Cetin, Mesut & Müller, Norbert. (2016). Neuroinflammation in Schizophrenia: A Critical Review and The Future. KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY. 26. 329-444. doi: 10.5455/bcp.20161123044657.
Mccutcheon, R. A., Krystal, J. H., Howes, O. D., 2 MRC London Institute of Medical Sciences, Imperial College London, Hammer-smith Hospital, London, UK; MRC London Institute of Medical Sciences Imperial College London Hammer-smith Hospital London UK, & 5 Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Psychiatry Yale University School of Medicine New Haven CT USA. (n.d.). Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.
Luvsannyam, E., Jain, M. S., Pormento, M. K. L., Siddiqui, H., Balagtas, A. R. A., Emuze, B. O., & Poprawski, T. (2022). Neurobiology of Schizophrenia: A Comprehensive Review. Cureus. doi: 10.7759/cureus.23959
Rybakowski, J. (2021). Etiopathogenesis of schizophrenia – the state of the art for 2021. Psychiatria Polska, 55(2), 261–274. doi: 10.12740/pp/132953
Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: a review. British Medical Bulletin, 114(1), 169–179. doi: 10.1093/bmb/ldv017
Mutschler E. (2016). Mutschler Farmakologia i Toksykologia. ISBN 978-83-7846-037-4
Correll, C. U., Solmi, M., Croatto, G., Kolton Schneider, L., Rohani-Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., Tiihonen, J., 2 Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry Zucker Hillside Hospital Northwell Health Glen Oaks NY USA, 5 Department of Mental Health, Ottawa Hospital, Ottawa, ON, Canada; Department of Mental Health Ottawa Hospital Ottawa ON Canada, 6 Ottawa Hospital Research Institute (OHRI) Clinical Epi-demiology Program, University of Ottawa, Ottawa, ON, Canada; Clinical Epi-demiology Program Ottawa Hospital Research Institute (OHRI University of Ottawa Ottawa ON Canada, & 14 Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Center for Psychiatry Research Stockholm City Council, Stockholm Sweden. (n.d.). Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors
Sieradzki, A. (2019). Schizophrenia and its health consequences as a public health problem. Nursing and Public Health, 9(4), 309–313. doi: 17219/pzp/110090
Sampogna, G., Di Vincenzo, M., Giuliani, L., Menculini, G., Mancuso, E., Arsenio, E., Cipolla, S., Della Rocca, B., Martiadis, V., Signorelli, M. S., & Fiorillo, A. (2023). A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia. Brain Sciences, 13(11), 1577. doi: 10.3390/brainsci13111577
Kaul, I., Sawchak, S., Walling, D. P., Tamminga, C. A., Breier, A., Zhu, H., Miller, A. C., Paul, S. M., & Brannan, S. K. (2024). Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia. JAMA Psychiatry, 81(8), 749. doi: 10.1001/jamapsychiatry.2024.0785
Hasan, A. H., & Abid, M. A. (2024). Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. Cureus. doi: 10.7759/cureus.71131
Boogaard, W. M. C., Komninos, D., & Vermeij, W. (2022). Chemotherapy Side-Effects: Not All DNA Damage Is Equal. Cancers, 14.
Azargoonjahromi, A. Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment. Clin Drug Investig 44, 471–493 (2024). doi: 10.1007/s40261-024-01377-9
Lejeune, J. A., Northrop, A., & Kurtz, M. (2021). A Meta-analysis of Cognitive Remediation for Schizophrenia: Efficacy and the Role of Participant and Treatment Factors. Schizophrenia Bulletin
Paul, S. M., Yohn, S. E., Popiolek, M., Miller, A. C., & Felder, C. C. (2022). Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. American Journal of Psychiatry, 179(9), 611–627. doi: 10.1176/appi.ajp.21101083
Laszlovszky, I., Barabássy, Á., & Németh, G. (2021). Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy, 38, 3652–3673
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P. H., Cipriani, A., Davis, J. M., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet, 394, 939–951
Qin, Y., Zhao, J., Yang, Y., Liu, Y., Xiang, H., Tong, J., & Huang, C. (2024). Association of HTR1A Gene Polymorphisms with Efficacy and Plasma Concentrations of Atypical Antipsychotics in the Treatment of Male Patients with Schizophrenia. Neuropsychiatric Disease and Treatment, 20, 185–193
Dean, B. (2024). IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia. Pharmacological Research, 210, 107510. doi: 10.1016/j.phrs.2024.107510
Best, M. W., Romanowska, S., Zhou, Y., Wang, L., Leibovitz, T., Onno, K., Jagtap, S., & Bowie, C. (2023). Efficacy of Remotely Delivered Evidence-Based Psychosocial Treatments for Schizophrenia-Spectrum Disorders: A Series of Systematic Reviews and Meta-Analyses. Schizophrenia Bulletin
https://biopharma.media/karxt-breakthrough-new-drug-for-schizophrenia-treatment-12000/
https://clinicaltrials.gov/study/NCT04659174
https://clinicaltrials.gov/study/NCT04820309
Sauder, C., Allen, L., Baker, E. K., Miller, A. C., Paul, S., & Brannan, S. (2022). Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Translational Psychiatry, 12
Diana Kwon (2024). New schizophrenia drug could treat Alzheimer’s disease doi: 10.1038/d41586-024-03707-5
COBENFY U.S. Prescribing Information https://packageinserts.bms.com/pi/pi_cobenfy.pdf
https://www.cobenfy.com/about#cobenfy-works-differntly
FDA approves 1st new drug for schizophrenia in more than 30 years - ABC News. (n.d.). Retrieved November 23, 2024, from https://abcnews.go.com/Health/fda-approves-1st-new-drug-schizophrenia-30-years/story?id=114070951
Solmi, M., Croatto, G., Piva, G., Rosson, S., Fusar-Poli, P., Rubio, J., Carvalho, A., Vieta, E., Arango, C., DeTore, N., Eberlin, E. S., Mueser, K., & Correll, C. (2022). Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. Molecular Psychiatry, 28, 354–368
Winter-Rossum, I., Weiser, M., Galderisi, S., Leucht, S., Bitter, I., Glenthøj, B., Hasan, A., Luykx, J., Kupchik, M., Psota, G., Rocca, P., Stefanis, N., Teitelbaum, A., Haim, M. B., Leucht, C., Kemmler, G., Schurr, T., Davidson, M., Kahn, R., … Huijsman, E. (2023). Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry
Published
August 5, 2025
Copyright (c) 2025 Daria Gliwa; Joanna Bączyk, Anna Krakowczyk, Marta Tworuszka
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
